ORA - Oxford University Research Archive

« Previous | 1 - 10 of 96 | Next »

1

Journal article

Strengthening clinical cancer research in the United Kingdom.

Stead, M, Cameron, D, Lester, N, et al.
2011-05-05

2

Journal article

Evaluating many treatments and biomarkers in oncology: a new design.

Kaplan, R, Maughan, T, Crook, A, et al.
2013-12-05

3

Conference

Preliminary phase IISOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (IRT) in patients (pts) with locally advanced rectal cancer (LARC).

Glynne-Jones, R, Sebag-Montefiore, D, McDonald, A, et al.
2004-07-15

4

Journal article

X-ACT: an important step on an unfinished journey.

Maughan, T
2012-07-05

5

Conference

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA

Taieb, J, Maughan, T, Bokemeyer, C, et al.
2012-06-05

6

Conference

Targeted therapies in the management of Colorectal cancer

Maughan, T
2011-09-05

7

Journal article

The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.

Türbachova, I, Schwachula, T, Vasconcelos, I, et al.
2013-11-05

8

Conference

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED

Maughan, T, Wilson, R, Seymour, M, et al.
2010-10-05

9

Journal article

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.

Adams, R, Meade, A, Wasan, H, et al.
2008-08-05

10

Journal article

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Adams, R, Brown, E, Brown, L, et al.
2017

« Previous
Next »
1
2
3
4
5
…
9
10

TO TOP